Search

everythinglearnresearchcommunity

for

Search:↓

Doctors recommend postoperative radiation for male breast cancer, advise against testosterone for vasomotor symptoms post-adrenalectomy, suggest non-hormonal treatments for atrophic vaginitis after mastectomy, note no specific treatment for anticoagulant-induced hair loss, and call for more research on silicosis from silicon carbide exposure.

Ferulic acid may help control menstrual cycle-related epilepsy by affecting female hormones.

Finasteride may cause sexual dysfunction by reducing epinephrine levels.

Estradiol-rich plasma can increase hair density faster and more effectively in male pattern baldness treatment than regular plasma.

Female pattern hair loss is different from male pattern hair loss and has unclear genetic causes.

Dr. Rodney Sinclair uses a detailed grading system to diagnose female pattern hair loss, recommends daily spironolactone and minoxidil for treatment, and believes genetics play a role in the condition.

Estrogens help reduce skin aging, and SERMs might offer similar benefits without the risks of hormone therapy.

Spironolactone can cause side effects like irregular bleeding, but lower doses may reduce these effects and still improve hirsutism.

New treatments for male hypogonadism are effective and should be personalized.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.

A man's breast enlargement from low-dose finasteride for hair loss didn't go away, even with treatment, and might be more common than reported.

The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.

A 5-year-old girl with McCune-Albright syndrome grew abnormal hair due to the drug tamoxifen.

A young woman with kidney failure had hair loss due to a common hormonal disorder, which improved with hormone therapy.

The document concludes that skin aging in women can be caused by UV exposure and hormonal changes, and treatments like hormone replacement therapy and various skin therapies can help.

Menopause causes dry skin, wrinkles, and hair changes, with hormone therapy helping but not recommended just for these issues.

Estetrol may help prevent hair loss and promote hair growth in women.

Tamoxifen can cause total hair loss but its benefits outweigh this side effect.

Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.

Estetrol (E4) may help treat female pattern hair loss by prolonging hair growth.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

Future osteoporosis treatments should focus on increasing bone growth, with many promising options available.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Tamoxifen may cause female hair loss by increasing androgen receptor expression.

Herbal hair gel with fenugreek seed extract was found to increase hair growth.

Gender-affirming hormone therapy affects metabolism differently based on treatment type.